about
ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cellsInterferon regulatory factor 8-deficiency determines massive neutrophil recruitment but T cell defect in fast growing granulomas during tuberculosisIL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activationCyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosisICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cellsCancer-driven dynamics of immune cells in a microfluidic environment.IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report.STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells.The tumor microenvironment: a pitch for multiple players.Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils.Mycobacterium tuberculosis PstS1 amplifies IFN-γ and induces IL-17/IL-22 responses by unrelated memory CD4+ T cells via dendritic cell activation.Organs on chip approach: a tool to evaluate cancer -immune cells interactions.TIM-3 as a molecular switch for tumor escape from innate immunity.The dual role of IRF8 in cancer immunosurveillance.Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment.Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen.Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.Type I IFN regulate DC turnover in vivo.Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.Eosinophils: The unsung heroes in cancer?A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells.Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic moleculesThe Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor ImmunityType I interferons produced by dendritic cells promote their phenotypic and functional activationICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cellsFrom Petri Dishes to Organ on Chip Platform: The Increasing Importance of Machine Learning and Image AnalysisBAX gene expression in melanoma metastasesDetection of C-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesionsMonoclonal gammopathies with a high MC elicit altered phenotypic and genotypic featuresPossible use of lymphoid CD subsets as prognostic markers for plasma cell dyscrasiasHigh-throughput analysis of cell-cell crosstalk in ad hoc designed microfluidic chips for oncoimmunology applicationsBasophils in Tumor Microenvironment and SurroundingsIL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell KillingTumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
P50
Q24672345-28C5A8BA-5133-4684-ADCD-1FC85F3D58CCQ27321749-A4AEE5D5-E11E-4784-8F0D-4D085BE6DA62Q28207915-A591CB85-5DD9-4692-BEC8-F904034182F2Q28300987-83CE3AA2-073E-4AB2-AA59-4AD7764F6CFCQ28304270-4609E5D5-05A8-487C-A0CA-688B5CD1E94CQ30843720-221AA3F5-D6B1-447D-9115-331B1C6A04C8Q36520732-FA087928-1057-4186-A061-CD60E00745EAQ37204229-88F1C9D0-FA79-49ED-B031-CE16E4B1B2D8Q37862244-4675725D-B9C7-43A8-911E-4B58CD27114AQ38101567-907266B3-2670-476B-9E02-4A455EE7B2E8Q38176613-1B91DB69-B327-40E4-8284-CF8277BCA513Q38746537-821ACB2F-AD8B-4499-8C27-A44A8C4F2A76Q38823705-36EA91BC-4803-4F2B-A184-517F16D884BCQ40146282-E2583D61-684F-40D8-B7D1-94F8C2AAFA88Q42261100-79DD99D3-552D-4172-BA34-801B2AA4E2BAQ42371821-807C9D8B-3E18-4A95-9737-FFAFCB3F8E57Q42583763-EB707B97-45B1-4E79-8FDA-D0B08F3EEA1DQ42931800-3CB955ED-7ABC-47AF-8703-1513EC7D3A36Q43916547-4158ECE0-FE9E-4D91-84E5-35441FE88537Q44266813-9BF2A763-A772-4062-B6F7-5572A9E2231BQ44527902-B5426EE4-E75B-4A92-9D32-FA49D684C34EQ44680243-23895FB9-669C-4213-ADB8-2FACA604640FQ45397464-97318B5D-0E1A-4974-B15A-362D5EB462D7Q47225787-D5EA39B9-C860-4224-8582-4E221426B030Q51520620-0A854C4C-2474-491D-8161-89F4A2CC49FCQ52385477-00DB54DF-F92D-4797-A53A-15416D53E286Q57022201-380C67AE-874F-4382-AFC9-E04BD37ACBEBQ59329322-99DA57DF-951A-4DCD-9AC3-E4B024E453C0Q61473768-FA2E6F68-3680-4124-983A-C04B864C68DBQ63309966-CB8E1A79-DF94-4285-9071-7E726524F10FQ64100767-C36C8959-5157-4805-B75D-6A33BA00C7E4Q71001838-FBBC7860-2978-4034-81C1-F8B506BDAE5BQ72144951-B95B0A48-C1AF-411B-83BF-7B188B339681Q77707190-5E693E48-CEAA-4E08-8EA9-C34214E8601EQ77707194-6F6FCD6D-4BD3-4139-9B86-896C8E378250Q89450660-49D26DEB-E7E7-46A5-9F6B-B2CF4A80D19BQ89613146-10BFFC9E-6E13-4BF3-9CE3-803E2CFF2A95Q91254181-EC45F19D-C3EF-46FD-AAFC-8629A4709E29Q91922734-FC6682DA-9C78-4DFE-9462-7D2FD1B59A07
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Fabrizio Mattei
@ast
Fabrizio Mattei
@en
Fabrizio Mattei
@es
Fabrizio Mattei
@nl
Fabrizio Mattei
@sl
type
label
Fabrizio Mattei
@ast
Fabrizio Mattei
@en
Fabrizio Mattei
@es
Fabrizio Mattei
@nl
Fabrizio Mattei
@sl
altLabel
Mattei Fabrizio Mattei F.
@en
prefLabel
Fabrizio Mattei
@ast
Fabrizio Mattei
@en
Fabrizio Mattei
@es
Fabrizio Mattei
@nl
Fabrizio Mattei
@sl
P214
P1053
J-6585-2016
P106
P1871
cnp01105764
P21
P214
P2798
P31
P3829
P496
0000-0002-5357-7773